drugset / Trial / NCT05347316

Colchicine Effect on Perivascular Inflammation Index on Coronary CTA

NCT05347316

Phase 1 Unknown 40 enrolled University of Sao Paulo General Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Inflammation is an important pillar of atherogenesis in coronary disease. Studies have documented the prognostic power of measuring coronary perivascular adipose tissue attenuation (PVAT) and its good correlation as an early inflammatory biomarker in the atherogenesis process, in addition to being a predictor for cardiovascular events in the future. Colchicine, a medication with well-documented anti-inflammatory action and with an impact on reducing cardiovascular outcomes, may have an action in reducing FAI (fat attenuation index). This study aims to evaluate the effect of colchicine in reducing coronary perivascular inflammation.

Timeline

Start
2022-03-07
Primary completion
2023-03-07
Completion
2025-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg